Evergreen Theragnostics News and Activities

Evergreen Theragnostics is owned by Lantheus Holdings.

Lantheus Holdings is one of the...

• Russell 3000;
• TOB Iconic 10,000.

Lantheus Holdings is a company listed under the stock ticker LNTH (US).

They are in:

• Pharmaceuticals50%
• Biotechnology50%

Acquisition, funding and merger involving Lantheus Holdings.

• Lantheus Holdings has acquired Evergreen Theragnostics (posted on April 2 2025).

View the org chart displaying its 4 main executives

Most searched biographies at Evergreen Theragnostics

• Dipesh Patel, General Manager and General Counsel
• Alison Tillbrook, Vice President of Human Resources
• Danny Singh, Manager, Logistics and Customer Service

Popular executive movements at Lantheus Holdings

• Andrew Stephens, Senior Vice President, Clinical Development, has left the company  (posted on May 29 2026).
• Jean-Claude Provost, Chief Science Officer, has left the company  (posted on May 29 2026).
• Paul Blanchfield, President , has left the company  (posted on November 11 2025).

Click here to view some more movements at Lantheus Holdings

Create your alert
to follow the executive moves at Evergreen Theragnostics.

Lantheus Holdings has 2,406 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
• NewLimit has just announced a $435 Million fundraising (posted on June 3 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Valerie Hanote - Non-Executive Director at Eurofins

Learn more about the Biotechnology industry

Press releases by Evergreen Theragnostics

• Clarity and Evergreen enter Targeted Copper Theranostics manufacturing agreement for US clinical trials
• Lantheus to Acquire Evergreen Theragnostics for Upfront Payment of $250 Million to Drive Strategic Evolution into Fully Integrated Radiopharmaceutical Leader
• MTTI partners with Evergreen to manufacture EvaThera platform of radiopharmaceuticals
• Clarity and Evergreen expand Targeted Copper Theranostics manufacturing
• Clovis Oncology and Evergreen Theragnostics Initiate Development and Manufacturing Services Agreement for Actinium-225-Labeled FAP-2286
• Evergreen Theragnostics Completes New Jersey Manufacturing Facility
• News
• News
• News
• Lantheus Completes Acquisition of Evergreen Theragnostics | Lantheus Holdings, Inc.
• View more press releases Close

Social media about Evergreen Theragnostics

• Evergreen Theragnostics on Wikipedia, Google News & Yahoo Finance
• Evergreen Theragnostics on LinkedIn, X (Twitter) & YouTube